GlaxoSmithKline Invests $20 Million in AIDS Research

GlaxoSmithKline Invests $20 Million in AIDS Research

GlaxoSmithKline has announced a partnership with University of North Carolina at Chapel Hill to start a research institute and company for curing HIV and AIDS. GlaxoSmithKline will contribute $20 million over the next five years to the research center, to be set up on the North Carolina campus. The company, Qura Therapeutics, will be jointly owned by the company and the university. [5/11/15]

Search